Brokerages expect TherapeuticsMD Inc (NASDAQ:TXMD) to post $4.59 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for TherapeuticsMD’s earnings. The highest sales estimate is $5.09 million and the lowest is $4.22 million. TherapeuticsMD reported sales of $4.42 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 3.8%. The business is scheduled to issue its next quarterly earnings report on Monday, November 5th.
According to Zacks, analysts expect that TherapeuticsMD will report full-year sales of $19.06 million for the current financial year, with estimates ranging from $17.47 million to $20.70 million. For the next fiscal year, analysts expect that the business will post sales of $128.64 million, with estimates ranging from $74.00 million to $180.20 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover TherapeuticsMD.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The firm had revenue of $3.80 million during the quarter, compared to analysts’ expectations of $4.23 million. TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. The business’s revenue for the quarter was down 11.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.10) earnings per share.
Shares of TherapeuticsMD stock traded up $0.06 during trading hours on Tuesday, reaching $4.82. The stock had a trading volume of 277,065 shares, compared to its average volume of 2,874,047. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -13.03 and a beta of 1.40. The company has a debt-to-equity ratio of 0.94, a current ratio of 7.88 and a quick ratio of 7.79. TherapeuticsMD has a 1 year low of $4.34 and a 1 year high of $7.66.
In related news, insider John C.K. Iv Milligan sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $1,525,000.00. Following the sale, the insider now directly owns 1,597,419 shares in the company, valued at approximately $9,744,255.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Robert G. Finizio sold 184,000 shares of the firm’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $6.24, for a total value of $1,148,160.00. Following the sale, the chief executive officer now owns 18,485,559 shares in the company, valued at $115,349,888.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,158,800 shares of company stock worth $12,946,562. Company insiders own 22.85% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Fox Run Management L.L.C. purchased a new stake in shares of TherapeuticsMD during the 2nd quarter valued at about $121,000. Managed Account Services Inc. purchased a new stake in shares of TherapeuticsMD during the 3rd quarter valued at about $117,000. Affiance Financial LLC purchased a new stake in shares of TherapeuticsMD during the 2nd quarter valued at about $156,000. Twin Focus Capital Partners LLC purchased a new stake in shares of TherapeuticsMD during the 2nd quarter valued at about $187,000. Finally, Xact Kapitalforvaltning AB raised its holdings in shares of TherapeuticsMD by 96.3% during the 1st quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock valued at $155,000 after buying an additional 15,600 shares during the period. Institutional investors and hedge funds own 66.13% of the company’s stock.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Featured Article: What is a Market Correction?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.